Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon‐α treatment in HBeAg‐positive chronic hepatitis B patients

• Published in: Journal of medical virology Vol. 90; no. 4; pp. 721 - 729
• Main Authors: Zhu, Ming‐Yu, Chen, Pei‐Zhan, Li, Jing, Yu, De‐Min, Huang, Dao, Zhu, Xue‐Juan, Han, Yue, Chen, Jie, Huang, Wei, Chen, Yong‐Yan, Gong, Qi‐Ming, Jiang, Jie‐Hong, Zhang, Dong‐Hua, Zhang, Yan, Zhang, Ji‐Ming, Zhang, Xin‐Xin
• Format: Journal Article
• Language: English
• Published: United States John Wiley and Sons Inc 01.04.2018
• Subjects: Adult; Alanine Transaminase - blood; Antigens, Neoplasm - blood; Antiviral Agents - administration & dosage; Biomarkers - blood; chronic hepatitis B; DNA, Viral - blood; Female; Follow-Up Studies; Hepatitis B e Antigens - blood; Hepatitis B Surface Antigens - blood; Hepatitis B, Chronic - diagnosis; Hepatitis B, Chronic - drug therapy; Hepatitis B, Chronic - pathology; Humans; Interferon-alpha - administration & dosage; M2BPGi; Male; Membrane Glycoproteins - blood; pegylated interferon‐α; Polyethylene Glycols - administration & dosage; Prognosis; Recombinant Proteins - administration & dosage; response; Retrospective Studies; ROC Curve; Serum - chemistry; Treatment Outcome; chronic hepatitis B; pegylated interferon-α; M2BPGi; response
• ISSN: 0146-6615; 1096-9071
• DOI: 10.1002/jmv.25010

Serum Mac‐2‐binding protein glycosylation isomer (M2BPGi) level was found to be a useful prognostic marker for hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B (CHB) patients treated with nucleoside/nucleotide analogs (NUCs) therapy, and the aim of our study is to evaluate the clinical implementation of M2BPGi level in the prediction of antiviral responses to pegylated‐interferon‐α (PEG‐IFN‐α) treatment in HBeAg‐positive CHB patients. Ninety‐six CHB patients who received PEG‐IFN‐α treatment for at least 48 weeks were recruited. The serum M2BPGi, alanine aminotransferase (ALT), hepatitis B surface antigen (HBsAg), HBeAg, and HBV DNA levels at baseline, weeks 4, 12, and 24 after PEG‐IFN‐α treatment were determined and their associations with antiviral responses were evaluated and the virological response (VR) rate and serological response (SR) rate after 48 weeks of treatment were 65.6% and 35.4%, respectively. Baseline serum M2BPGi level was significantly different between VR and non‐VR (P = 0.002) or SR and non‐SR groups (P = 0.012). Multivariate analyses suggested that baseline serum M2BPGi level was independently associated with VR and SR of PEG‐IFN‐α treatment at week 48. The area under the ROC curve (AUC) of baseline M2BPGi was 0.682 in predicting VR, which was superior to HBsAg (AUC = 0.566) or HBV DNA (AUC = 0.567). The AUC of baseline M2BPGi in predicting SR was 0.655, which was also higher than that of HBsAg (AUC = 0.548) or HBV DNA (AUC = 0.583). These results suggested that baseline serum M2BPGi level was a novel predictor of VR and SR for PEG‐IFN‐α treatment in HBeAg‐positive CHB patients.